The Current View on Hypercholesterolemia after the ‘Heart Protection Study’ – Do We Need New Strategies?

Publisher： Karger

E-ISSN： 1424-0556|2|4|201-203

ISSN： 1422-9528

Source： Heart Drug, Vol.2, Iss.4, 2002-11, pp. : 201-203

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

ACE Inhibitors in Heart Failure: What More Do We Need to Know?

By Demers Catherine   Mody Anita   Teo Koon K.   McKelvie Robert S.  

American Journal of Cardiovascular Drugs, Vol. 5, Iss. 6, 2005-01 ,pp. : 351-359

Adis International

Access to resources Recommend Favorite

Supplementary protection certificates on reformulations and new uses after Neurim: where do we go from here?

By Duncan Garreth  

Pharmaceutical Patent Analyst, Vol. 2, Iss. 2, 2013-03 ,pp. : 157-159

Future Science

Access to resources Recommend Favorite

Why Do We Need New Drug Classes for HIV Treatment and Prevention?

By  

Current Topics in Medicinal Chemistry, Vol. 16, Iss. 12, 2016-03 ,pp. : 1343-1349

Bentham Science Publishers

Access to resources Recommend Favorite

Transporter pharmacogenetics: do we need function? Do we need motion?

By Pastor-Anglada Marçal  

Pharmacogenomics, Vol. 14, Iss. 13, 2013-10 ,pp. : 1537-1540

Future Medicine

Access to resources Recommend Favorite

Getting to the Heart of the Matter: New Technologies for Atherosclerosis and Hypercholesterolemia

By  

Pharmaceutical Innovation, Vol. 11, Iss. 4, 2002-06 ,pp. : 2-11

Adis International

Access to resources Recommend Favorite